A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors
Sponsor: AnHeart Therapeutics Inc.
This PHASE1 trial investigates Solid Tumors and is currently completed. AnHeart Therapeutics Inc. leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Jul 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Jul 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
May 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AnHeart Therapeutics Inc.
- Nuvation Bio Inc.
For direct contact, visit the study record on ClinicalTrials.gov .